Robert W. Baird initiated coverage on shares of GTX (NASDAQ:GTXI) in a report published on Tuesday, November 21st, Marketbeat reports. The firm issued an outperform rating and a $17.00 price target on the biopharmaceutical company’s stock.
Separately, Stifel Nicolaus assumed coverage on shares of GTX in a report on Thursday, November 9th. They issued a buy rating on the stock.
Shares of GTX (NASDAQ:GTXI) traded down $0.38 during trading hours on Tuesday, hitting $12.01. 16,122 shares of the stock were exchanged, compared to its average volume of 79,408. GTX has a 52 week low of $2.73 and a 52 week high of $13.35.
GTX (NASDAQ:GTXI) last issued its quarterly earnings results on Tuesday, November 14th. The biopharmaceutical company reported ($0.53) EPS for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.25). research analysts forecast that GTX will post -1.61 EPS for the current year.
Several hedge funds and other institutional investors have recently made changes to their positions in the company. Abingworth LLP acquired a new position in shares of GTX during the third quarter valued at about $2,781,000. Caxton Corp acquired a new position in shares of GTX during the third quarter valued at about $531,000. Finally, Bank of New York Mellon Corp acquired a new position in shares of GTX during the second quarter valued at about $124,000. Hedge funds and other institutional investors own 11.57% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This report was originally published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this report on another website, it was copied illegally and republished in violation of U.S. and international copyright and trademark law. The original version of this report can be accessed at https://ledgergazette.com/2017/12/07/robert-w-baird-begins-coverage-on-gtx-inc-gtxi.html.
GTX Company Profile
GTx, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecules for the treatment of cancer, including treatments for breast and prostate cancer, and other medical conditions. The Company is engaged in the development of selective androgen receptor modulators (SARMs).
Receive News & Ratings for GTx Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GTx Inc. and related companies with MarketBeat.com's FREE daily email newsletter.